Delivery Order SPE2DB25D3018-SPE2DB25FUYLE
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a specialty pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, valued at $11,500.66, is scheduled for completion by August 14, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a $5,506.33 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price contract, which is set to be completed by August 21, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The delivery will be performed at the contractor's corporate...
- The Defense Logistics Agency awarded a $33,781.22 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in treating autoimmune conditions. The contract is a firm fixed-price delivery order with no set-aside designation, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a $5,303.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency has awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a brand-name pharmaceutical product used in the treatment of autoimmune conditions. This competitively awarded, firm fixed-price delivery order was executed on August 27, 2025, with an ultimate completion date of August 28, 2025. The contract will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $9,166.50 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of autoimmune conditions. This contract type represents a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The order was executed on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at...
- The Defense Logistics Agency awarded a $41,926.99 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls pharmaceutical supply. This non-competitive delivery order, awarded on August 13, 2025, with an ultimate completion date of August 14, 2025, represents a child contract under AmerisourceBergen's larger federal pharmaceutical supply vehicle. The product will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $2,030.54 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a medication used to treat autoimmune conditions. This firm fixed price delivery order, with an ultimate completion date of August 12, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,265.90 delivery order on July 18, 2025, for HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 21, 2025. This competitive award, issued under firm fixed pricing with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product...
- The Defense Logistics Agency awarded a delivery order valued at $16,204.30 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania—the...
- SPE2DB25D3018Indefinite Delivery Contract
- SPE2DB25D3018-SPE2DB25FUYLEDelivery Order
The Defense Logistics Agency awarded a $11,971.22 delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026, which serves as the company's primary vehicle for supplying pharmaceutical products and medical supplies to support military healthcare systems globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly for the Department of Defense and veteran healthcare systems. The company's extensive portfolio of federal contracts with DLA demonstrates its capability to deliver a comprehensive range of pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. The delivery order is scheduled for ultimate completion by September 3, 2025, supporting the Defense Health Agency and other government healthcare systems through the company's established prime vendor relationship with DLA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.0k | 9/2/25 |